Cargando…
Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells
Recently approved cancer drugs remain out-of-reach to most patients due to prohibitive costs and only few produce clinically meaningful benefits. An untapped alternative is to enhance the efficacy and safety of existing cancer drugs. We hypothesized that the response to topoisomerase II poisons, a v...
Autores principales: | More, Piyush, Goedtel-Armbrust, Ute, Shah, Viral, Mathaes, Marianne, Kindler, Thomas, Andrade-Navarro, Miguel A., Wojnowski, Leszek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731103/ https://www.ncbi.nlm.nih.gov/pubmed/31523390 http://dx.doi.org/10.18632/oncotarget.27112 |
Ejemplares similares
-
Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations
por: More, Piyush, et al.
Publicado: (2023) -
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
por: Deng, Shiwei, et al.
Publicado: (2014) -
Structural and Functional Similarity of Amphibian Constitutive Androstane Receptor with Mammalian Pregnane X Receptor
por: Mathäs, Marianne, et al.
Publicado: (2014) -
Correction: Structural and Functional Similarity of Amphibian Constitutive Androstane Receptor with Mammalian Pregnane X Receptor
por: Mathäs, Marianne, et al.
Publicado: (2016) -
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014)